Compare ClearPoint Neuro Inc (CLPT) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Marsh & McLennan Companies, Inc. — how do they compare? ClearPoint Neuro Inc trades at $14.99 (market cap $454.21M), while Marsh & McLennan Companies, Inc. trades at $189.05 (market cap $91.27B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 200.9× ClearPoint Neuro Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.07% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | MRSH | |
|---|---|---|
Market Cap | $454.21M | $91.27B |
Sector | Health | Financials |
52-Week High | $29.60 | $211.21 |
52-Week Low | $8.66 | $157.32 |
Enterprise Value | $488.79M | $111.95B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.56, down slightly by 0.07% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth to $42 million but missed earnings estimates with a loss of $0.38 per share, reflecting ongoing investment in clinical and preclinical services. Despite negative net income margins and cash flow challenges, analyst consensus remains unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of growth initiatives in neuro drug delivery and regulatory progress with partners, though high valuation multiples and persistent losses pose significant risks. Near-term catalysts include Q3 2026 earnings and partner developments, but investors face volatility from operational cash burn and competitive pressures.
Marsh & McLennan (MRSH) trades at $190.79, down 0.45% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat estimates with EPS of $2.96 versus $2.88 expected, driven by 6% revenue growth. The company announced the acquisition of Accel to expand Midwest operations, enhancing its insurance and consulting services. Valuation metrics show a P/E of 23.35 and ROE of 25.72%, reflecting robust profitability.
Outlook remains positive with a consensus price target of $202.89, offering ~6% upside. Risks include margin pressure from rising expenses and soft P&C pricing. Institutional activity is mixed, with Bank of America reducing its stake while others like Ashton Thomas Securities added positions. The stock presents a growth opportunity amid strategic expansions, though investors should monitor expense management and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
